JP2014523900A - セルピン融合ポリペプチド及びその使用方法 - Google Patents

セルピン融合ポリペプチド及びその使用方法 Download PDF

Info

Publication number
JP2014523900A
JP2014523900A JP2014519049A JP2014519049A JP2014523900A JP 2014523900 A JP2014523900 A JP 2014523900A JP 2014519049 A JP2014519049 A JP 2014519049A JP 2014519049 A JP2014519049 A JP 2014519049A JP 2014523900 A JP2014523900 A JP 2014523900A
Authority
JP
Japan
Prior art keywords
polypeptide
fusion protein
aat
human
serpin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014519049A
Other languages
English (en)
Japanese (ja)
Inventor
ピー．エッケルマン ブレンダン
シー．ティマー ジョン
エル．ヌイ ピーター
ビー．ゲンター グラント
ディベロー クイン
Original Assignee
インヒブルクス リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インヒブルクス リミティド ライアビリティ カンパニー filed Critical インヒブルクス リミティド ライアビリティ カンパニー
Publication of JP2014523900A publication Critical patent/JP2014523900A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
JP2014519049A 2011-06-28 2012-06-28 セルピン融合ポリペプチド及びその使用方法 Pending JP2014523900A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161502055P 2011-06-28 2011-06-28
US61/502,055 2011-06-28
US201161570394P 2011-12-14 2011-12-14
US61/570,394 2011-12-14
US201161577204P 2011-12-19 2011-12-19
US61/577,204 2011-12-19
US201261638168P 2012-04-25 2012-04-25
US61/638,168 2012-04-25
PCT/US2012/044730 WO2013003641A2 (en) 2011-06-28 2012-06-28 Serpin fusion polypeptides and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017134043A Division JP6674604B2 (ja) 2011-06-28 2017-07-07 セルピン融合ポリペプチド及びその使用方法

Publications (1)

Publication Number Publication Date
JP2014523900A true JP2014523900A (ja) 2014-09-18

Family

ID=47424806

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014519049A Pending JP2014523900A (ja) 2011-06-28 2012-06-28 セルピン融合ポリペプチド及びその使用方法
JP2017134043A Active JP6674604B2 (ja) 2011-06-28 2017-07-07 セルピン融合ポリペプチド及びその使用方法
JP2020018783A Pending JP2020078325A (ja) 2011-06-28 2020-02-06 セルピン融合ポリペプチド及びその使用方法
JP2022069976A Pending JP2022109968A (ja) 2011-06-28 2022-04-21 セルピン融合ポリペプチド及びその使用方法
JP2024110442A Pending JP2024138397A (ja) 2011-06-28 2024-07-09 セルピン融合ポリペプチド及びその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017134043A Active JP6674604B2 (ja) 2011-06-28 2017-07-07 セルピン融合ポリペプチド及びその使用方法
JP2020018783A Pending JP2020078325A (ja) 2011-06-28 2020-02-06 セルピン融合ポリペプチド及びその使用方法
JP2022069976A Pending JP2022109968A (ja) 2011-06-28 2022-04-21 セルピン融合ポリペプチド及びその使用方法
JP2024110442A Pending JP2024138397A (ja) 2011-06-28 2024-07-09 セルピン融合ポリペプチド及びその使用方法

Country Status (28)

Country Link
US (8) US8980266B2 (enExample)
EP (2) EP2726092B1 (enExample)
JP (5) JP2014523900A (enExample)
KR (6) KR102084944B1 (enExample)
CN (3) CN110066340B (enExample)
AU (4) AU2012275287B2 (enExample)
BR (1) BR112013033799A2 (enExample)
CA (2) CA2839619C (enExample)
CY (1) CY1122195T1 (enExample)
DK (1) DK2726092T3 (enExample)
ES (1) ES2746052T3 (enExample)
HR (1) HRP20191652T1 (enExample)
HU (1) HUE046156T2 (enExample)
IL (3) IL276534B2 (enExample)
IN (1) IN2013MN02441A (enExample)
LT (1) LT2726092T (enExample)
ME (1) ME03473B (enExample)
MX (2) MX356517B (enExample)
NZ (1) NZ744257A (enExample)
PL (1) PL2726092T3 (enExample)
PT (1) PT2726092T (enExample)
RS (1) RS59368B1 (enExample)
RU (4) RU2698655C2 (enExample)
SG (2) SG10201601621PA (enExample)
SI (1) SI2726092T1 (enExample)
SM (1) SMT201900520T1 (enExample)
UA (1) UA124083C2 (enExample)
WO (1) WO2013003641A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017537888A (ja) * 2014-10-27 2017-12-21 インヒブルクス リミティド パートナーシップ セルピン融合ポリペプチド及びその使用方法
CN110869346A (zh) * 2017-07-27 2020-03-06 密歇根大学董事会 纤维蛋白溶酶原活化物抑制因子-1(pai-1)抑制剂和使用方法
JP2022509517A (ja) * 2018-10-29 2022-01-20 スピン セラピューティクス， エルエルシー アルファ－１－アンチトリプシン欠乏症のための組成物及び方法
JP2022542519A (ja) * 2019-08-01 2022-10-04 サープラス テクノロジー エルエルシー 酸化耐性セルピン

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2723370A4 (en) * 2011-06-24 2015-06-03 Univ Colorado Regents COMPOSITIONS, PROCESS AND USE OF ALPHA-1-ANTITRYPHIN FUSION MOLECULES
US10400029B2 (en) * 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
SG10201601621PA (en) 2011-06-28 2016-04-28 Inhibrx Llc Serpin fusion polypeptides and methods of use thereof
WO2013003649A2 (en) * 2011-06-28 2013-01-03 Inhibrx Llc Wap domain fusion polypeptides and methods of use thereof
WO2013106589A1 (en) * 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
KR101509020B1 (ko) * 2013-05-22 2015-04-14 (주)입디 알파 1 안티트립신 융합 분자에 대한 조성물, 방법 및 용도
US20170190762A1 (en) 2014-06-11 2017-07-06 Beth Israel Deaconess Medical Center, Inc. Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases
WO2016014612A2 (en) * 2014-07-23 2016-01-28 Inova Diagnostics, Inc. Compositions and methods for the diagnosis of rheumatoid arthritis
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US11422719B2 (en) 2016-09-15 2022-08-23 Pure Storage, Inc. Distributed file deletion and truncation
US12031144B2 (en) 2017-03-29 2024-07-09 Cornell University Oxidation-resistant AAT gene therapy
CN109705211B (zh) 2017-10-26 2020-08-18 苏州复融生物技术有限公司 一种IgG1 Fc单体及其应用
AU2018374285B2 (en) 2017-12-01 2024-06-27 Csl Behring Llc Methods for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation
AU2020301529A1 (en) 2019-06-24 2022-01-06 Universität Stuttgart TNFR2 agonists with improved stability
CA3158862A1 (en) * 2019-11-21 2021-05-27 Daniel Lawrence Polypeptide inhibitors of neutrophil elastase activity and uses thereof
CN110964094B (zh) * 2019-12-20 2021-11-02 华中科技大学 人源白细胞蛋白酶抑制因子及其重组制备与应用
CN112341538A (zh) * 2020-10-27 2021-02-09 苏州复融生物技术有限公司 一种Fc单体多肽及其应用
US20240301381A1 (en) * 2021-01-26 2024-09-12 National Research Council Of Canada Ace2-receptor ectodomain fusion molecules and uses thereof
GB202102258D0 (en) 2021-02-17 2021-03-31 Arecor Ltd Novel composition
US20250049898A1 (en) * 2021-12-22 2025-02-13 The Regents Of The University Of California Compositions and methods for wound healing
IL316983A (en) 2022-05-16 2025-01-01 Sanofi Aatd Inc Effective dosage of recombinant SERPIN-FC fusion protein for use in a method of treating AAT deficiency in a subject
CN115466323B (zh) * 2022-09-13 2025-07-01 宁波博睿瀚达生物科技有限公司 一种分离分泌性白细胞蛋白酶抑制因子的方法
EP4483951A1 (en) * 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
WO2025083294A2 (en) 2024-02-29 2025-04-24 Ageronix SA Aat-fc fusion protein
WO2025219443A1 (en) 2024-04-19 2025-10-23 Uniqure Biopharma B.V. Nucleic acid for a1at regulation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004697A1 (fr) * 1992-08-11 1994-03-03 Tsumura & Co. Nouveau derive d'elafine
JP2002537810A (ja) * 1999-03-01 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトセルピンタンパク質
JP2004537970A (ja) * 2000-12-18 2004-12-24 アライバ ファーマシューティカルズ，インコーポレイティド 多機能性プロテアーゼインヒビターおよびそれらの疾患治療における使用
JP2007504144A (ja) * 2003-08-26 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド ア ボディー コーポレイト セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法
CA2758445A1 (en) * 2009-04-22 2010-10-28 Alteogen, Inc. In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
WO2012178102A2 (en) * 2011-06-24 2012-12-27 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
EP1189931B1 (en) 1999-07-02 2006-06-21 Genentech, Inc. Peptide compounds that bind her2
JP2003515325A (ja) * 1999-12-01 2003-05-07 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４ジスルフィドコアドメイン含有（ｆｄｃｄ）ポリヌクレオチド、ポリペプチド、および抗体
WO2001079444A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc Albumin fusion proteins
FR2814957B1 (fr) 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
EP1333839A1 (en) * 2000-11-08 2003-08-13 Prometic Biosciences Inc. Method for the treatment of inflammation
DK1724284T3 (da) 2000-12-07 2009-11-02 Lilly Co Eli GLP-1 fusionsproteiner
AU2002248184C1 (en) * 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1415664A1 (en) * 2002-10-30 2004-05-06 Switch Biotech Aktiengesellschaft Use of alpha 1-antichymotrypsin in combination with alpha-1-antitrypsin for treating/preventing diabetes associated or poorly healing arterial wounds
US7427595B1 (en) * 2002-12-12 2008-09-23 Cornell Research Foundation, Inc. Use of proepithelin to promote wound repair and reduce inflammation
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
MXPA05013564A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion.
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP2239273B1 (en) * 2003-11-13 2013-10-09 Hanmi Science Co., Ltd. A pharmaceutical composition comprosing an immunoglobulin fc as a carrier
US7914771B2 (en) * 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
EP2067789A1 (en) 2004-04-13 2009-06-10 F. Hoffmann-La Roche Ag Anti-P selectin antibodies
EP2194064A1 (en) 2004-05-13 2010-06-09 Eli Lilly & Company FGF-21 fusion proteins
KR101323411B1 (ko) 2004-08-03 2013-10-30 트랜스테크 파르마, 인크. Ｒａｇｅ 융합 단백질 및 이의 사용 방법
KR20070041781A (ko) 2004-08-11 2007-04-19 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인 융합 단백질
US7399746B2 (en) 2004-10-06 2008-07-15 Mcgill University Agents for wound healing
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP4652414B2 (ja) 2004-11-12 2011-03-16 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
ES2707152T3 (es) * 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US8163881B2 (en) * 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
JP4067557B2 (ja) 2005-06-03 2008-03-26 持田製薬株式会社 抗ｃｄ１４抗体融合蛋白質
EP1910542B1 (en) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
CA2618951A1 (en) 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
RS58231B1 (sr) * 2005-11-23 2019-03-29 Acceleron Pharma Inc Antagonisti aktivin-actriia i primene za stimulaciju rasta kostiju
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
US8367615B2 (en) 2006-03-30 2013-02-05 Research Foundation Of City University Of New York Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
EA017733B1 (ru) * 2006-08-28 2013-02-28 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
US20110020269A1 (en) 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
EP2662449B1 (en) * 2007-05-30 2017-02-15 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
WO2009045508A1 (en) * 2007-10-02 2009-04-09 Research Foundation Of City University Of New York Novel protein transduction domains derived from secretory leukocyte protease inhibitor
AR064713A1 (es) 2007-12-28 2009-04-22 Consejo Nac Invest Cient Tec Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
AU2009274738B2 (en) * 2008-07-23 2012-12-13 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
CA2732449A1 (en) 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
EP3482769B1 (en) 2008-12-19 2024-05-29 MacroGenics, Inc. Covalent diabodies and uses thereof
SG174862A1 (en) 2009-04-10 2011-11-28 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorder
SE533763C2 (sv) 2009-05-04 2010-12-28 Lars Hammar Upphängningsanordning
WO2011005998A1 (en) 2009-07-08 2011-01-13 The Curators Of The University Of Missouri Method to develop high oleic acid soybeans using conventional soybean breeding techniques
AU2010319327B2 (en) 2009-11-13 2015-08-13 Five Prime Therapeutics, Inc. Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
GB201003559D0 (en) 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
WO2012003290A2 (en) 2010-06-30 2012-01-05 University Of Maryland, Baltimore Dental composites comprising nanoparticles of amorphous calcium phosphate
HUE033205T2 (en) 2010-12-23 2017-11-28 Janssen Biotech Inc Active protease-resistant antibody fc mutants
HRP20181690T4 (hr) 2011-03-29 2025-01-03 Roche Glycart Ag Varijante protutijela fc
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
WO2013003649A2 (en) 2011-06-28 2013-01-03 Inhibrx Llc Wap domain fusion polypeptides and methods of use thereof
SG10201601621PA (en) 2011-06-28 2016-04-28 Inhibrx Llc Serpin fusion polypeptides and methods of use thereof
CA2840711C (en) * 2011-07-01 2023-10-17 Biogen Idec Ma Inc. Arginine-free tnfr:fc-fusion polypeptide compositions and methods of use
WO2013106589A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
CA2877363A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
BR112014028368A2 (pt) 2012-06-27 2017-11-14 Hoffmann La Roche método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
HUE029634T2 (en) 2012-08-02 2017-03-28 Hoffmann La Roche A method for producing soluble FcR as an Fc fusion with an inert immunoglobulin Fc region and its uses
WO2014089375A1 (en) 2012-12-05 2014-06-12 Boston Strategics Corporation Protein expression enhancing polypeptides
CN203917563U (zh) 2014-03-27 2014-11-05 陈广煌 一种切角模具
US20170190762A1 (en) * 2014-06-11 2017-07-06 Beth Israel Deaconess Medical Center, Inc. Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004697A1 (fr) * 1992-08-11 1994-03-03 Tsumura & Co. Nouveau derive d'elafine
JP2002537810A (ja) * 1999-03-01 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトセルピンタンパク質
JP2004537970A (ja) * 2000-12-18 2004-12-24 アライバ ファーマシューティカルズ，インコーポレイティド 多機能性プロテアーゼインヒビターおよびそれらの疾患治療における使用
JP2007504144A (ja) * 2003-08-26 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド ア ボディー コーポレイト セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法
CA2758445A1 (en) * 2009-04-22 2010-10-28 Alteogen, Inc. In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
WO2012178102A2 (en) * 2011-06-24 2012-12-27 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. BIOL. CHEM., 2003, 278(34), PP.31796-31806, JPN6016015872, ISSN: 0003306140 *
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281(33), PP.23514-23524, JPN6017038059, ISSN: 0003653909 *
NATURE BIOTECHNOLOGY, 2010, 28(2), PP.157-159, JPN6017038060, ISSN: 0003653910 *
PROC. NATL. ACAD. SCI. U.S.A., 2010, 107(8), PP.3552-3557, JPN6016015869, ISSN: 0003306139 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020180157A (ja) * 2014-10-27 2020-11-05 インヒブルクス，インコーポレイティド セルピン融合ポリペプチド及びその使用方法
JP2017537888A (ja) * 2014-10-27 2017-12-21 インヒブルクス リミティド パートナーシップ セルピン融合ポリペプチド及びその使用方法
CN110869346B (zh) * 2017-07-27 2024-03-29 密歇根大学董事会 纤维蛋白溶酶原活化物抑制因子-1(pai-1)抑制剂和使用方法
CN110869346A (zh) * 2017-07-27 2020-03-06 密歇根大学董事会 纤维蛋白溶酶原活化物抑制因子-1(pai-1)抑制剂和使用方法
JP2020528906A (ja) * 2017-07-27 2020-10-01 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）阻害剤および使用方法
US12390427B2 (en) 2017-07-27 2025-08-19 Eastern Michigan University Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use
US11426368B2 (en) 2017-07-27 2022-08-30 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use
JP7291119B2 (ja) 2017-07-27 2023-06-14 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）阻害剤および使用方法
JP2024123234A (ja) * 2018-10-29 2024-09-10 スピン セラピューティクス， エルエルシー アルファ－１－アンチトリプシン欠乏症のための組成物及び方法
JP2022509517A (ja) * 2018-10-29 2022-01-20 スピン セラピューティクス， エルエルシー アルファ－１－アンチトリプシン欠乏症のための組成物及び方法
JP7731288B2 (ja) 2018-10-29 2025-08-29 スピン セラピューティクス， エルエルシー アルファ－１－アンチトリプシン欠乏症のための組成物及び方法
US12497441B2 (en) 2018-10-29 2025-12-16 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
JP2022542519A (ja) * 2019-08-01 2022-10-04 サープラス テクノロジー エルエルシー 酸化耐性セルピン

Also Published As

Publication number Publication date
JP6674604B2 (ja) 2020-04-01
US20130330769A1 (en) 2013-12-12
US20200102371A1 (en) 2020-04-02
RU2642310C2 (ru) 2018-01-24
LT2726092T (lt) 2019-10-10
DK2726092T3 (da) 2019-09-30
CY1122195T1 (el) 2020-11-25
AU2012275287A1 (en) 2014-01-16
CN110066340A (zh) 2019-07-30
HUE046156T2 (hu) 2020-02-28
KR20210032558A (ko) 2021-03-24
RU2017145308A (ru) 2019-02-18
RU2014102583A (ru) 2015-08-10
ES2746052T3 (es) 2020-03-04
RU2728861C1 (ru) 2020-07-31
SG10201811256QA (en) 2019-01-30
MX381183B (es) 2025-03-12
US20210002352A1 (en) 2021-01-07
MX356517B (es) 2018-06-01
US20250011394A1 (en) 2025-01-09
JP2024138397A (ja) 2024-10-08
KR102756547B1 (ko) 2025-01-21
RU2698655C2 (ru) 2019-08-28
SI2726092T1 (sl) 2019-11-29
RU2727452C1 (ru) 2020-07-21
MX2013015323A (es) 2014-06-23
US20130011398A1 (en) 2013-01-10
CA2839619A1 (en) 2013-01-03
IN2013MN02441A (enExample) 2015-06-12
PT2726092T (pt) 2019-10-08
US11965017B2 (en) 2024-04-23
KR20250012200A (ko) 2025-01-23
NZ619023A (en) 2015-07-31
US20210024613A1 (en) 2021-01-28
EP2726092B1 (en) 2019-06-19
US11827691B2 (en) 2023-11-28
AU2012275287B2 (en) 2017-10-05
CA2839619C (en) 2021-11-16
HRP20191652T1 (hr) 2019-12-13
CN110551223A (zh) 2019-12-10
RU2020124172A (ru) 2022-01-21
NZ744257A (en) 2022-10-28
RU2017145308A3 (enExample) 2019-02-18
AU2019202904A1 (en) 2019-05-16
AU2017279724A1 (en) 2018-01-25
UA124083C2 (uk) 2021-07-21
IL276534B1 (en) 2025-07-01
KR20200027041A (ko) 2020-03-11
US20150147325A1 (en) 2015-05-28
IL276534B2 (en) 2025-11-01
WO2013003641A3 (en) 2013-03-21
EP2726092A4 (en) 2015-08-19
ME03473B (me) 2020-01-20
JP2022109968A (ja) 2022-07-28
KR20140054000A (ko) 2014-05-08
JP2020078325A (ja) 2020-05-28
CA3132298A1 (en) 2013-01-03
WO2013003641A2 (en) 2013-01-03
KR20230114318A (ko) 2023-08-01
EP3569243A1 (en) 2019-11-20
IL312872A (en) 2024-07-01
AU2019202904B2 (en) 2021-01-07
CN103917563A (zh) 2014-07-09
IL276534A (en) 2020-09-30
EP2726092A2 (en) 2014-05-07
SG10201601621PA (en) 2016-04-28
AU2017279724B2 (en) 2019-03-14
KR102084944B1 (ko) 2020-04-17
JP2018008956A (ja) 2018-01-18
CN110066340B (zh) 2024-06-25
KR102231139B1 (ko) 2021-03-24
RS59368B1 (sr) 2019-11-29
BR112013033799A2 (pt) 2017-02-14
SMT201900520T1 (it) 2019-11-13
US10723785B2 (en) 2020-07-28
AU2021202131B2 (en) 2023-01-12
AU2021202131A1 (en) 2021-05-06
US10730929B2 (en) 2020-08-04
PL2726092T3 (pl) 2019-11-29
US20180179264A1 (en) 2018-06-28
IL230209B (en) 2020-08-31
US8980266B2 (en) 2015-03-17
KR20220003656A (ko) 2022-01-10
US9920109B2 (en) 2018-03-20

Similar Documents

Publication Publication Date Title
JP6674604B2 (ja) セルピン融合ポリペプチド及びその使用方法
JP2014528913A (ja) Ｗａｐドメイン融合ポリペプチド及びその使用方法
JP6737781B2 (ja) セルピン融合ポリペプチド及びその使用方法
RU2846432C2 (ru) Слитые серпиновые полипептиды и способы их применения
HK40017627A (en) Serpin fusion polypeptides and methods of use thereof
HK40012209B (zh) 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
HK40012209A (en) Serpin fusion polypeptides and methods of use thereof
HK1197544B (en) Serpin fusion polypeptides and methods of use thereof
HK1197544A (en) Serpin fusion polypeptides and methods of use thereof
NZ727846B2 (en) Serpin fusion polypeptides and methods of use thereof
NZ619023B2 (en) Serpin fusion polypeptides and methods of use thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161025

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170707

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170807

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20171006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181219